Healthcare
Liquidia Corporation(LQDA)
Live Price
Offline$71.23
-0.56% today
1Y Change
+455.44%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $3.40B
- Revenue Growth
- +1031.2%
- EPS Growth
- +51.8%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Liquidia Corporation (LQDA) is a Healthcare stock with a market cap of $3.40B and listed on NASDAQ. The stock last traded around $71.23 and up 455.4% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +1031.2%, EPS growth of +51.8%, a dividend yield of 0.0%. What stands out right now is revenue +1031.2%, EPS +51.8%, free cash flow +59.3% with operating margin -32.5% and ROIC -20.5%. Valuation already assumes a fairly strong business story at price/sales 21.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines LQDA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1031.2% vs +7.6% peer median
Operating Margin
Below sector median
-32.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1031.2% and EPS at +51.8%, with operating margin around -32.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.2% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -4.0% | +4.5% | +20.1% |
2026 Mar 5, 2026 | +87.5% | +4.4% | +8.9% | +9.2% |
2025 Nov 3, 2025 | +91.1% | +10.7% | +8.1% | +22.1% |
Benchmark Edge
LQDA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LQDA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LQDA Max Drawdown
-35.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LQDA and SPY.
Company Overview
Liquidia Corporation
NASDAQ Capital Market
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
- Leadership
- Roger A. Jeffs
- IPO Date
- Jul 26, 2018
- Employees
- 170
- Street Address
- 419 Davis Drive
- Mailing
- Morrisville, NC, 27560
- Region
- Morrisville, NC, US
- Reporting Currency
- USD
- Investor Line
- 919 328 4400
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 21.4
- Price/Book
- 75.0
Growth
- Revenue
- +1031.2%
- EPS
- +51.8%
- Free Cash Flow
- +59.3%
Profitability
- Gross Margin
- 97.2%
- Operating Margin
- -32.5%
- Net Margin
- -43.5%
- ROE
- -209.3%
- ROIC
- -20.5%
Balance Sheet
- Debt/Equity
- 4.42
- Current Ratio
- 1.40
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.